InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | chiang yao-chung | Director | Purchase | 200 | $1.68 | $336.00 | 700 | View ↗ | |
| 2026-04-29 | chiang yao-chung | Director | Purchase | 100 | $1.75 | $175.00 | 500 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | $124K+499.0% | $21K | — | — |
| Cost of revenues | -$21K+59.6% | -$53K | — | — |
| Gross profit (loss) | $103K+422.9% | -$32K | — | — |
| Research and development expenses (including amounts for related party of $947,084 and $1,418,887 for the years ended December 31, 2025 and 2024, respectively) | $7.7M-7.9% | $8.4M | — | — |
| Selling, general and administrative expenses | $6.3M+17.6% | $5.4M-4.3% | $5.6M-34.0% | $8.5M |
| Total operating expenses | $14.1M+2.1% | $13.8M+6.6% | $13.0M-15.8% | $15.4M |
| Loss from operations | -$14.0M-1.1% | -$13.8M-4.8% | -$13.2M | — |
| Interest expense | -$712K-15.5% | -$616K-327.5% | -$144K-169.4% | -$54K |
| Issuance cost of senior secured convertible note measured at fair value | -$308K | — | -$526K | $0 |
| Fair value change of senior secured convertible note | -$276K | — | $94K | $0 |
| Other income (expenses), net | -$68K-137.9% | $179K | — | — |
| Total non-operating expenses, net | -$780K+23.6% | -$1.0M-81.3% | -$563K-1748.4% | -$30K |
| Net loss before income taxes | -$14.8M+0.6% | -$14.9M-7.9% | -$13.8M+1.7% | -$14.0M |
| Provision for income taxes | $800+0.0% | $800+0.0% | $800 | $0 |
| Net loss | -$14.8M+0.6% | -$14.9M-7.9% | -$13.8M+1.7% | -$14.0M |
| Net loss per common share - basic | -$3.46+55.8% | -$7.82-132.7% | -$3.36 | — |
| Net loss per common share - diluted | -$3.46+55.8% | -$7.82-132.7% | -$3.36 | — |
| Weighted-average shares used in computing net loss per common share-basic | $4.3M+124.7% | $1.9M-53.6% | $4.1M | — |
| Weighted-average shares used in computing net loss per common share-diluted | $4.3M+124.7% | $1.9M-53.6% | $4.1M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
VASRO: Ainos Expands Smell AI from Industrials into Healthcare Infrastructure, Reinforcing AI Infrastructure Positioning and Multi-Vertical Scalability
Ainos, MacKay Memorial Hospital and Topco Scientific Partner to Advance Smell AI Deployment in High-Risk Hospital Environments
VASRO Research Highlights Ainos' Smell AI Commercial Progress and 2026 Deployment Momentum
Ainos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026